We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Tretinoin: An Established Long-term Safety Profile—Reply

Kenneth A. Katz, MD, MSc, MSCE
Arch Dermatol. 2009;145(9):1064-1065. doi:10.1001/archdermatol.2009.207.
Text Size: A A A
Published online


In reply

Powers et al raise 4 points in seeking to allay concerns I raised about tretinoin safety in light of the VATTC trial.1 None is convincing.

First, Powers et al are technically correct that an abstract reporting VATTC study results published in 20052 stated that excess mortality in the tretinoin group compared with the placebo group was not statistically significant after adjusting for confounders. But a more complete VATTC study report published in 20093 stated that excess mortality in the tretinoin group—122 of 566 participants (22%), compared with 90 of 565 (16%) participants in the placebo group—was statistically significant (P = .02), even after adjusting for confounders, and therefore cannot be attributed to imbalances in randomization. Moreover, the magnitude of the mortality difference is clinically significant. The number of VATTC study participants exposed to tretinoin per excess death—the “number needed to harm”—was only 18.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





September 1, 2009
William Powers Jr, PhD, DABT; Stanley S. Shapiro, PhD; Annie Heremans, MD, PhD
Arch Dermatol. 2009;145(9):1063-1064. doi:10.1001/archdermatol.2009.206.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Are topical retinoids teratogenic? G Ital Dermatol Venereol Published online Sep 6, 2016;
Topical retinoids for acne. Semin Cutan Med Surg 2016;35(2):50-6.